Systemic sclerosis & Raynaud's
Capturing the Range of Disease Involvement in Localized Scleroderma: The Localized Scleroderma Total Severity Scale
Authors' conclusion
We developed a new LS measure for assessing cutaneous and extracutaneous severity and have shown it to be reliable, valid, and responsive.
Study context
- Population
- Patients with juvenile localized scleroderma (jLS); prospective cohort initiating treatment
- Outcome
- Measurement properties of LoTSS
Methodological detailsconsensus process, multicriteria decision analysis, case vignettes, prospective patient cohort, Developed as a weighted measure by consensus (literature review, surveys, case vignettes, multicriteria decision analysis); feasibility assessed in larger CARRA groups
- Consensus process
- Multicriteria decision analysis
- Case vignettes
- Prospective patient cohort
- Developed as a weighted measure by consensus (literature review, surveys, case vignettes, multicriteria decision analysis); feasibility assessed in larger CARRA groups
Performance
As reported in the abstract
- Construct validity: strong positive correlation with Physician Global Assessment (PGA) of severity and damage; weak positive correlation with PGA-Activity, as expected
- Responsive, with a small effect size
- Moderate-to-excellent inter-rater reliability
- Discriminated between patient subsets: higher scores with greater disease burden and functional limitation
- Modules for skin, extracutaneous and craniofacial manifestations
Original publication
Capturing the Range of Disease Involvement in Localized Scleroderma: The Localized Scleroderma Total Severity Scale. Arthritis Care Res (Hoboken). Published 15 February 2024. doi:10.
Composed by AI from the published abstract and checked against it. How Briefs are made →